Looking for Responders among Women with Chronic Pelvic Pain Treated with a Comicronized Formulation of Micronized Palmitoylethanolamide and Polydatin

Table 1

Description of studies of which databases has been assessed at individual patient level. Included cases are reported in the last column at the right side.

	Treatment	Disease	Pain assessment	Enrolment	Eligible cases	Included cases
Dell’Anna and De Marzi [29]	Um-PEA 200 mg; m-(PEA/Pol) 400 mg/40 mg 3 times daily for four months	Endometriosis	NRS	Prospective	Single arm: 16	14
Di Francesco and Pizzagallo [22]	m-(PEA/Pol) 400 mg/40 mg two times daily for six months	Endometriosis	NRS	Randomized	An arm: 10	9
Dionisi and Senatori [30]	m-(PEA/Pol) 400 mg/40 mg two times daily for two months, plus topical adelmidrol	Vulvodynia/vestibulodynia	NRS	Prospective	Single arm: 34	17
Giugliano et al. [31]	m-(PEA/Pol) 400 mg/40 mg two times daily for three months	Endometriosis	VAS	Prospective	Two arms (but no comparator arm): 19 and 28	15 and 18
Indraccolo and Barbieri [20]	m-(PEA/Pol) 400 mg/40 mg two times daily for three months	Endometriosis	VAS	Small series	4 cases	4
Murina et al. [32]	m-(PEA/Pol) 400 mg/40 mg two times daily for two months	Vestibulodynia	VAS	Randomized	An arm: 10	9
Stocco and Schievano [34]	m-(PEA/Pol) 400 mg/40 mg two times daily for two months	Miscellaneous symptoms	VAS/NRS	Prospective	Single arm: 13 (male and female)	7

m-PEA: micronized palmitoylethanolamide; um-PEA: ultramicronized palmitoylethanolamide; Pol: polydatin.